Meeder Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Meeder Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-44	Closed	-$7K	–	2123
2020 Q1	$7K	Buy	+44	New	+$7.44K	﹤0.01%	1647
2019 Q2	–	Sell	-34	Closed	-$7K	–	2048
2019 Q1	$7K	Buy	34 +20	+143%	+$4.41K	﹤0.01%	1320
2018 Q4	$2K	Sell	14 -19	-58%	-$3.79K	﹤0.01%	1564
2018 Q3	$8K	Buy	+33	New	+$5.33K	﹤0.01%	1207
2018 Q2	–	Sell	-11	Closed	-$2K	–	1578
2018 Q1	$2K	Buy	11 +4	+57%	+$898	﹤0.01%	1369
2017 Q4	$1K	Buy	+7	New	+$1.5K	﹤0.01%	1559

Other funds holding CRBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Meeder Asset Management's CRBP Position: Q2 2020 in Review

Meeder Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2020, closing a stake of 44 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in CRBP in Q4 2017 and held it in 6 quarters. The position peaked at $8K in Q3 2018. 140 funds tracked by Wall St. Rank hold CRBP as of Q2 2020.

Meeder Asset Management reported no remaining Corbus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 44 Corbus Pharmaceuticals shares in Q2 2020, an estimated $7K.
Meeder Asset Management first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Meeder Asset Management's Corbus Pharmaceuticals position peaked at $8K in Q3 2018.
140 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.